SS-31 (elamipretide): a synthetic tetrapeptide that targets cardiolipin
SS-31, also known as elamipretide, is a synthetic tetrapeptide (D-Arg–2′,6′-dimethyl-Tyr–Lys–Phe-NH₂) from the Szeto–Schiller family of cell-penetrating peptides. In research models it is notable for concentrating strongly in the inner mitochondrial membrane, where it associates with cardiolipin — a signature phospholipid that shapes the folded cristae and supports the electron transport chain. Cross-linking mass spectrometry studies have mapped SS-31 near several cardiolipin-binding proteins involved in oxidative phosphorylation. Because cardiolipin is susceptible to oxidative damage, researchers study SS-31 as a tool for understanding how membrane–lipid interactions influence mitochondrial structure and function in vitro and in isolated mitochondria. This is a mechanistic research context only, not a statement about any use in humans.
How SS-31 works: surface electrostatics and protein interactions
Two complementary bodies of laboratory evidence describe how SS-31 engages membranes. Biophysical studies in model lipid bilayers show that the peptide partitions into anionic membranes largely through electrostatic attraction, altering lipid packing and lowering the membrane's surface potential without disrupting the bilayer. Proteomic cross-linking studies in isolated mitochondria identified roughly a dozen interacting proteins across several enzyme complexes, many linked to ATP production and 2-oxoglutarate metabolism. In aged mitochondria, these reports describe increased oxygen consumption and reduced hydrogen peroxide generation. These are observations from in vitro and ex vivo systems; they characterise a proposed mechanism and do not demonstrate any outcome in humans.
SS-31 in clinical research: what sets it apart from most research peptides
Unlike most research peptides, SS-31/elamipretide has progressed into formal clinical evaluation for selected mitochondrial and cardiac conditions, meaning human trial data exist and can be examined. Precision matters here: as of writing, elamipretide is not an approved medicine in the EU or elsewhere, and clinical results across indications have been mixed, with several endpoints not met. Its presence in clinical trials reflects regulatory and scientific processes, not proof of efficacy or safety for any general use. For a research audience this distinction is important — trial registration and peer-reviewed reports offer a fuller picture of the evidence, but they do not convert a research compound into an approved therapy.
MOTS-c: a peptide encoded by mitochondrial DNA
MOTS-c (mitochondrial open reading frame of the 12S rRNA, type c) is a very different molecule. First described in 2015, it is a 16-amino-acid peptide encoded not in the nuclear genome but within the mitochondrial 12S ribosomal RNA gene, placing it among the "mitochondrial-derived peptides." In cellular studies it can translocate to the nucleus under metabolic stress and influence gene-expression programs. This origin is what makes MOTS-c scientifically interesting: it positions the mitochondrion as a source of signalling molecules, not merely a site of energy production. Research on MOTS-c is largely exploratory and mechanistic, spanning cell culture and animal models.
The MOTS-c mechanism: AMPK signalling in cell and animal models
The most studied signalling route for MOTS-c involves AMP-activated protein kinase (AMPK). In vitro work indicates that MOTS-c interferes with the folate one-carbon cycle, leading to accumulation of AICAR, an endogenous AMPK activator; increased NAD+ has also been reported. In mouse models, MOTS-c has been associated with changes in glucose handling and lipid metabolism in skeletal muscle and fat. Human data remain limited and largely observational — for example, circulating MOTS-c levels have been reported to rise with physical activity and to correlate with metabolic markers. No approved therapeutic use exists, and controlled human efficacy trials are lacking. The evidence should therefore be read as predominantly in vitro and animal.
Two peptides, two mechanisms: how to read the evidence
Placed side by side, the two peptides illustrate how different meanings the term "mitochondrial peptide" can carry. SS-31 is a synthetic, externally applied tetrapeptide that acts at the membrane–lipid interface and has reached human trials; MOTS-c is an endogenous, genetically encoded 16-mer studied mainly as a metabolic signalling molecule in cells and animals. They share a mitochondrial theme but not a mechanism, an evidence base, or a regulatory status. Honest reading means labelling each finding by system — in vitro, animal, or human — and resisting the temptation to transfer conclusions from one peptide to the other. Neither is an approved medicine, and neither should be framed around human benefit.
Research use only (RUO) and quality
All products referenced here are supplied strictly for research use only (izključno za raziskovalne namene) and are not intended for human or veterinary use, diagnosis, or treatment. Nothing above is medical advice or a therapeutic claim. Because reproducible research depends on well-characterised material, peptid.si provides laboratory-verified purity for every product: identity and purity are confirmed by mass spectrometry (masna spektrometrija) and high-performance liquid chromatography (tekočinska kromatografija, HPLC), and a public certificate of analysis (certifikat analize, COA) is published for every batch (serija) in the COA Vault, so researchers can verify exactly what they receive.
References / Links
- Chavez JD, Tang X, Campbell MD, Reyes G, et al. (2020). Mitochondrial protein interaction landscape of SS-31. Proceedings of the National Academy of Sciences (PNAS). PubMed
- Mitchell W, Ng EA, Tamucci JD, Boyd KJ, et al. (2020). The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action. Journal of Biological Chemistry. PubMed
- Zheng Y, Wei Z, Wang T (2023). MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology. Frontiers
- Lee C, Kim KH, Cohen P (2016). MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radical Biology and Medicine. PubMed
